Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has received a “Buy” rating from Rodman & Renshaw, which initiated coverage on the biopharmaceutical company with an $8.00 price target. The rating is based on the potential of Lucid-MS, the company’s lead drug candidate for progressive multiple sclerosis (MS). Lucid-MS is described as a potentially first-in-class non-immunomodulatory small molecule designed to address neurodegeneration and disability progression in patients with progressive forms of MS, a condition where therapeutic options are currently limited. The firm’s $8.00 price target reflects its valuation of Quantum BioPharma’s development pipeline, with Lucid-MS at the forefront.
The significance of this rating lies in the urgent need for effective treatments for progressive MS. Unlike relapsing-remitting MS, which has seen a surge in disease-modifying therapies, progressive MS has fewer approved options, and existing treatments often fail to halt disability progression. Lucid-MS aims to fill this gap by targeting the underlying mechanisms of the disease, specifically myelin degradation. In preclinical models, Lucid-MS has shown the ability to prevent and reverse myelin degradation, which is the fundamental process that leads to disability in MS. If successful in clinical trials, Lucid-MS could become a cornerstone therapy for patients with progressive MS, potentially altering the disease trajectory and improving quality of life for millions worldwide.
Quantum BioPharma is dedicated to building a portfolio of innovative assets for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of Lucid-MS, a patented new chemical entity. The company’s pipeline also includes other drug candidates at various stages of development, but Lucid-MS is the most advanced and holds the greatest promise for near-term value creation.
The company’s strategy extends beyond Lucid-MS. Quantum BioPharma has also developed UNBUZZD, a product aimed at alcohol misuse, and has spun out its over-the-counter version to Unbuzzd Wellness Inc. (UWI), a company led by industry veterans. Quantum retains a 19.48% ownership stake in UWI (as of June 30, 2026) and is entitled to royalty payments of 7% of sales from UNBUZZD until total payments reach $250 million, after which the royalty rate drops to 3% in perpetuity. This arrangement provides Quantum with a potential stream of recurring revenue that could support its research and development efforts. Additionally, Quantum retains 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses, ensuring it can leverage its intellectual property in the regulated pharmaceutical market.
For investors, the ‘Buy’ rating from Rodman & Renshaw is a positive signal, but it is essential to consider the risks inherent in drug development. Lucid-MS is still in preclinical stages, and its success is not guaranteed. Clinical trials are costly and time-consuming, and many promising candidates fail to demonstrate efficacy in humans. However, the potential market for a disease-modifying therapy in progressive MS is substantial, and if Lucid-MS receives regulatory approval, it could address a significant unmet medical need.
The announcement also highlights the growing interest in non-immunomodulatory approaches to treating MS. Traditional MS therapies often modulate the immune system to reduce inflammation, but they may not directly address neurodegeneration. Lucid-MS’s mechanism of action, which focuses on myelin repair and protection, could represent a paradigm shift in how progressive MS is treated. This approach has attracted attention from the medical community, and the positive rating from a reputable financial firm adds credibility to the company’s efforts.
Quantum BioPharma’s stock is traded on both the NASDAQ and the Canadian Securities Exchange, providing investors with access to its potential upside. The company’s newsroom at https://nnw.fm/QNTM offers the latest updates on its progress, and more information about Lucid-MS can be found at https://nnw.fm/8uqwL. As with any investment in biotech, potential investors should conduct thorough due diligence and consider the volatility and risks associated with clinical-stage companies.
In summary, the ‘Buy’ rating from Rodman & Renshaw underscores the potential of Lucid-MS to become a significant player in the treatment of progressive MS. With its novel mechanism and strong preclinical data, Quantum BioPharma is positioning itself to make a meaningful impact on a disease that affects millions. The coming years will be critical as the company moves Lucid-MS into clinical development and seeks to bring this promising therapy to patients.
